Physician profile
Eric D Dostal
NPI 1851310429
$6,125.09
in general payments reported to CMS, 2019-2025
16 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,917 · 2020: $65.90 · 2021: $150 · 2022: $415 · 2023: $496 · 2024: $634 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708 · Consulting Fee: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.88 |
| Consulting Fee | $870.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,414.16 | 2019-2025 | Acuvue |
| Coopervision INC. | $1,629.87 | 2019-2021 | |
| Oyster Point Pharma, INC. | $812.83 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $378.46 | 2019-2025 | Precision7, Precision 7, Dailies Total1 |
| Bausch & Lomb Americas INC. | $166.38 | 2023-2025 | Infuse, Miebo |
| Visioneering Technologies, INC. | $127.27 | 2020-2023 | |
| Allergan, INC. | $104.29 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $100.95 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $73.43 | 2024 | Lipiflow System Activator II (Disposable |
| Novartis Pharmaceuticals Corporation | $71.64 | 2021-2023 | |
| Biotissue Holdings INC. | $59.05 | 2022-2024 | |
| Dompe US, INC. | $50.85 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.69 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $43.62 | 2019 | |
| Sun Pharmaceutical Industries INC. | $29.30 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.30 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dostal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.